Abstract

Immunglobulin Substitution Therapy in Hematological Patients with secondary Antibody Deficiency Abstract. Hematological malignancies and immunochemotherapy are frequently associated with secondary cellular and humoral immunodeficiencies. Due to the growing application of effective therapeutic antibodies, and cellular therapies specifically targeting and hence depleting antibody producing cells (B- and plasma cells) the incidence of secondary antibody deficiencies in the daily practice is increasing. This article will provide a short overview of the etiology of secondary antibody deficiencies in hematological patients. Then, it will discuss the efficacy and indication of immunoglobulin substitution therapy in these patients and finally address the choice of the respective preparation.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.